ArticleOncoTargets and therapy2020
Peripheral Blood Leukocyte N6-methyladenosine is a Noninvasive Biomarker for Non-small-cell Lung Carcinoma.
Article in OncoTargets and therapy, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 30 citations in OpenAlex.
- The relevance of mJournal of cancer research and clinical oncology · 2026Review
- RNA Methylation in Cancer Metabolism: from Mechanisms to Therapeutic Opportunities.International journal of biological sciences · 2026Review
- RNA modifications in health and disease: from mechanistic insights to therapeutic applications.Precision clinical medicine · 2025Review
- Biomarkers for the diagnosis of indeterminate pulmonary nodules: are we there yet?Journal of thoracic disease · 2025Review
- Abnormal changes in metabolites caused by mJournal of advanced research · 2025Review
- Progression of mCell death discovery · 2024Review
- NCancer cell international · 2024Article
- FTO in Lung Cancer: Its Progression and Therapeutic Potential.Combinatorial chemistry & high throughput screening · 2024Review
- Review
- RNA mMolecular oncology · 2023Review
- Diagnostic value of aberrant decreased 5-Methylcytosine RNA modification in leukocytes for non-small cell lung cancer.Journal of Cancer · 2023Article
- Crosstalk among mJournal of hematology & oncology · 2022Review
- Methyladenosine Modification in RNAs: From Regulatory Roles to Therapeutic Implications in Cancer.Cancers · 2022Review
- The regulation and potential roles of m6A modifications in early embryonic development and immune tolerance at the maternal-fetal interface.Frontiers in immunology · 2022Review
- Implications of m6A methylation and microbiota interaction in non-small cell lung cancer: From basics to therapeutics.Frontiers in cellular and infection microbiology · 2022Review
- Comprehensive Analysis of Gene Signatures of m6ARNA Methylation Regulators in Lung Adenocarcinoma and Development of a Risk Scoring System.Journal of immunology research · 2022Article
- mMolecular cancer · 2021Article
- YTHDF1 Promotes Cyclin B1 Translation through mCells · 2021Article
- NCancer communications (London, England) · 2021Review
- Epitranscriptomics of Ischemic Heart Disease-The IHD-EPITRAN Study Design and Objectives.International journal of molecular sciences · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundN6-methyladenosine (m6A) triggers a new layer of epi-transcription. However, the potential noninvasive screening and diagnostic value of peripheral blood m6A for cancer are still unknown. Here, we intend to investigate whether leukocyte m6A can be a novel biomarker for non-small-cell lung cancer (NSCLC). MATERIALS AND
methodsPeripheral blood was collected from 119 NSCLC patients and 74 age-matched healthy controls. Total RNA was isolated from leukocytes for m6A measurement, and clinical information of participants was reviewed. The sensitivity, specificity, and area under the curve (AUC) of m6A for cancer diagnosis were evaluated by the receiver-operating characteristic (ROC) curve analysis. Flow cytometry and the Human Protein Atlas (HPA) database were used to characterize m6A in leukocyte differentials. Pearson's correlation was applied to indicate the relationship between m6A level and hematology variables. qPCR and bioinformatic analysis were used to identity the expression of m6A regulators in leukocyte.
resultsLeukocyte m6A was significantly elevated in 119 NSCLC patients compared with 74 healthy controls (
conclusionLeukocyte m6A represents a potential noninvasive biomarker for NSCLC screening, monitoring and diagnosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.